Preservation of thoracic spine microarchitecture by alendronate: comparison of histology and microCT.
The effect of bisphosphonates on trabecular microarchitecture may contribute to the reduced risk of vertebral fracture with treatment independent of the bone volume. Trabecular structure was examined at the twelfth thoracic vertebra after 2 years of treatment of two groups of ovariectomized baboons on high and low doses of alendronate, compared with ovariectomized and non-ovariectomized controls. Standard 2D histological measurements showed that alendronate treatment of ovariectomized animals resulted in significantly higher total trabecular length and a lower marrow star volume in comparison with ovariectomized controls indicating preservation of connectivity. Similarly when the vertebrae were examined using a novel thick slice technique that combines 2D and 3D information, ovariectomy produced a significantly higher number of "real" trabecular termini in comparison with normal. When ovariectomized animals were treated with increasing doses of alendronate, fewer "real" termini were seen. MicroCT analysis (2D and 3D) correlated well with the histological measurements, although more variability and less discrimination between groups was seen, with no statistically significant differences with alendronate treatment. Reduced vertebral fracture risk with alendronate may be due to a combination of factors including the increased bone volume, reduced turnover and greater mineralization reported by others. Added to this is now suggested the preservation of several aspects of vertebral cancellous architecture, with microscopy the most sensitive method of analysis.
Hordon
L D
LD
School of Biomedical Sciences, Worsley Medical and Dental Building, University of Leeds, Leeds, UK. lesley.hordon@midyorks.nhs.uk
Itoda
M
M
Shore
P A
PA
Shore
R C
RC
Heald
M
M
Brown
M
M
Kanis
J A
JA
Rodan
G A
GA
Aaron
J E
JE
D019386:Alendronate / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000008:administration & dosage* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006651:Histocytochemistry; D006652:Histological Techniques / Q000379:methods*; D010052:Ovariectomy; D010215:Papio; D013904:Thoracic Vertebrae / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology; D013997:Time Factors; D014057:Tomography, X-Ray Computed / Q000379:methods*; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D019386:Alendronate